Status:
COMPLETED
Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®
Lead Sponsor:
LG Life Sciences
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
To compare the pharmacokinetic characteristic of LBEC0101 25mg with the active comparator, Enbrel® 25 mg.
Eligibility Criteria
Inclusion
- Healthy males, 20 to 45 years of age the moment of screening
- Body mass index is between 18.0 and 30.0 kg/m
Exclusion
- The tuberculosis patient or latent tuberculosis patient
- Hypersensitivity response to the test and comparator drugs
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2011
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01145950
Start Date
June 1 2010
End Date
January 1 2011
Last Update
February 18 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea